Literature DB >> 24492363

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

Guanpingsheng Luo1, Teclegiorgis Gebremariam, Hongkyu Lee, John E Edwards, Laura Kovanda, Ashraf S Ibrahim.   

Abstract

We studied the in vitro and in vivo efficacies of the investigational drug isavuconazole against mucormycosis due to Rhizopus delemar. Isavuconazole was effective, with MIC and minimal fungicidal concentration (MFC) values ranging between 0.125 and 1.00 μg/ml. A high dose of isavuconazole prolonged the survival time and lowered the tissue fungal burden of cyclophosphamide/cortisone acetate-treated mice infected with R. delemar and was as effective as a high-dose liposomal amphotericin B treatment. These results support the further development of this azole against mucormycosis.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24492363      PMCID： PMC4023778          DOI： 10.1128/AAC.02301-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Zygomycosis: reemergence of an old pathogen.

Authors:  Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

3.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

4.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.

Authors:  J C Bowman; G K Abruzzo; J W Anderson; A M Flattery; C J Gill; V B Pikounis; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

Authors:  Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

9.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011.

Authors:  Robyn Neblett Fanfair; Kaitlin Benedict; John Bos; Sarah D Bennett; Yi-Chun Lo; Tolu Adebanjo; Kizee Etienne; Eszter Deak; Gordana Derado; Wun-Ju Shieh; Clifton Drew; Sherif Zaki; David Sugerman; Lalitha Gade; Elizabeth H Thompson; Deanna A Sutton; David M Engelthaler; James M Schupp; Mary E Brandt; Julie R Harris; Shawn R Lockhart; George Turabelidze; Benjamin J Park
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245
View more
  22 in total

1.  Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P Wiederhold; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Isavuconazonium: first global approval.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.

Authors:  J Viljoen; N Azie; A-H Schmitt-Hoffmann; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

4.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.

Authors:  Oliver A Cornely; Angelika Böhme; Anne Schmitt-Hoffmann; Andrew J Ullmann
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

6.  Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Authors:  Anuradha Chowdhary; Pradeep Kumar Singh; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Abdullah Alqarihi; Priya Uppuluri; Nkechi Azie; John E Edwards; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

8.  Isavuconazole Diffusion in Infected Human Brain.

Authors:  Claire Rouzaud; Vincent Jullien; Anne Herbrecht; Bruno Palmier; Simona Lapusan; Marjolaine Morgand; Romain Guéry; Amélie Dureault; François Danion; Stéphanie Puget; Lauriane Goldwirt; Fanny Lanternier; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 9.  Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.

Authors:  Matt Shirley; Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

10.  Isavuconazole for Treatment of Experimental Fungal Endophthalmitis Caused by Aspergillus fumigatus.

Authors:  John M Guest; Pawan Kumar Singh; Sanjay G Revankar; Pranatharthi H Chandrasekar; Ashok Kumar
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.